Randomized trial comparing three fixed combinations of prostaglandins/prostamide with timolol maleate

Jaime Pablo Kelly Rigollet
Joan Anton Ondategui
Angels Pasto
Laura Lop

Institut Català de la Salut,
Centre de Atenció Primària MANSO, Eixample esquerra, Barcelona, Spain

The results of this were first presented in the World Glaucoma Congress, Boston (8–11 July 2009)

Introduction

To evaluate the long-term efficacy and safety of 3 commercially available fixed combinations of prostaglandin analogs or a prostamide with timolol maleate in patients with primary open angle glaucoma or ocular hypertension.

Methods

In this randomized, prospective, single-blind study, intraocular pressure (IOP) was measured after a 1-month washout period and pachymetry was performed before randomizing patients to latanoprost 50 µg/timolol 5 mg/1 mL (L/T), bimatoprost 300 µg/timolol 5 mg/1 mL (B/T), or travoprost 40 µg/timolol 5 mg/1 mL (T/T). IOP was measured monthly for 6 months and then at 12 months by an investigator blinded to the study drug. Adverse reactions were recorded.

Results

128 cases were included in the study. The 3 treatment groups had similar baseline characteristics and comparable IOP. All 3 combinations decreased IOP by at least 6 mmHg and IOP remained below 21 mmHg throughout the study. At 12 months L/T achieved greater reduction in IOP than the other 2 fixed combinations, but the difference between L/T and B/T was not statistically significant. At 6 months, more B/T-treated patients reported red eye (P < 0.05 vs L/T and T/T). At 12 months, fewer adverse reactions were reported, with no cases of red eye reported for L/T (P = 0.03 vs B/T).

Conclusions

All 3 combinations are effective at lowering IOP but at 12 months L/T and B/T were found to be more effective than T/T. Treatments were well tolerated after 12 months but L/T showed less hyperemia than B/T throughout the study (P < 0.05).

Keywords: bimatoprost/timolol, fixed combinations, intraocular pressure, latanoprost/timolol, ocular hypertension, primary open angle glaucoma, travoprost/timolol.

Introduction

The term glaucoma covers a group of chronic optical neuropathies in which ganglion cell damage is associated with a loss of visual field.1 Many patients with ocular hypertension will develop glaucoma.2-4 As high intraocular pressure (IOP) is one of the most important risk factors for glaucoma,1-6 most treatments focus on reducing IOP. Trabeculectomy7 and laser trabecuoplasty8 have been the main, nonpharmacological therapeutic options, but these procedures have potential side effects.

As an alternative, a number of different drugs have become available over the last 3 decades; the β-blocker timolol was introduced in the late 1970s.9 Prostaglandin analogs were introduced in the late 1990s10 and have proved to be more effective at lowering IOP than β-blockers.11,12 More recently, fixed combinations of these agents have been approved: latanoprost with timolol maleate (latanoprost 50 µg and timolol 5 mg/1 mL).
was approved in April 2002. In October 2006, 2 further combinations were approved: travoprost/timolol (travoprost 40 μg and timolol 5 mg/1 mL) and bimatoprost/timolol (bimatoprost 300 μg and timolol 5 mg/1 mL).

Since few data are available comparing the effectiveness and safety of some of these combinations, and no study has compared the 3 available fixed combinations of prostaglandins and timolol, we conducted a 12-month randomized study to compare the hypotensor effect of these 3 combinations and their tolerability in terms of local events reported by patients with primary open angle glaucoma or ocular hypertension who had used more than 1 antiglaucoma drug previously.

**Patients and method**

**Participants**

Patients were eligible for participation in the study if they met the following inclusion criteria: age ≥ 18 years, primary open angle glaucoma or ocular hypertension (IOP ≥ 21 mmHg at baseline), and previously treated with at least 2 hypotensor drugs. Exclusion criteria were known contraindication to any of the study treatments, use of any medicine that might affect IOP, abnormal ocular condition or symptom preventing the patient from entering the study according to the investigator’s judgment, and pregnancy or lactancy. The sample was recruited from outpatients attending the “Centre d’Atenció Primària Manso” in Barcelona, Spain. All participants signed the informed consent before any study procedures were conducted.

Patients were assigned to medical interventions at random once we tested that patients fulfilled all the selection criteria of the study. Random codes were obtained by means of a computerized algorithm after the study protocol and related documents were approved by the Scientific Research Committee of the site.

The algorithm produced a block of 9 codes for patients allowing a balanced distribution 1:1:1 of study subjects to the 3 medical interventions evaluated. Eyes from the same patients always received the same medical intervention.

In order to evaluate IOP reduction at 12 months with the 3 commercially available fixed combinations, it was estimated that 111 cases that met all inclusion criteria and none of the exclusion criteria should be included, 37 in each treatment arm.

A sample of 37 cases per treatment arm allowed the detection of a reduction ≥ 2 mmHg with a significance level of 95%, power of 80%, in bilateral contrast, assuming a common standard deviation of 4.

**Interventions**

After a 1-month washout period without any antiglaucoma drugs, the patients were randomized to 1 of the 3 combination treatments: latanoprost 50 μg and timolol 5 mg/1 mL (L/T); travoprost 40 μg and timolol 5 mg/1 mL (T/T); or bimatoprost 300 μg and timolol 5 mg/1 mL (B/T). These treatments were administered at night according to the labeling. Prior to treatment, baseline pachymetry was undertaken with the DHG 5100E pachymeter and IOP was measured by Goldman applanation tonometry.

Evaluations were carried out every month by the same masked observer until month 6 and then at month 12. The patients were aware of the treatment that they used. All the examinations were performed between 8:00 and 10:30 AM. IOP was measured and patients were asked about side effects and adverse events. The primary efficacy variable of the study was mean change in IOP between baseline and month 12.

**Statistical analyses**

The primary efficacy variable was IOP reduction with the 3 commercially available fixed combinations.

Baseline patient characteristics are described using mean (SD) values for quantitative variables; absolute and relative frequency distributions were used for qualitative variables. The Kolmogorov–Smirnov test was used to test for normal distribution. Reductions in IOP in follow-up visits are expressed in absolute and relative changes versus the baseline value in each study group.

The changes from baseline in IOP were calculated using measurements of central tendency (mean) and dispersion (95% confidence interval [CI]). Groups were compared by analysis of variance (ANOVA) and t tests for independent samples.

**Results**

Of the initial group of 141 cases, 13 were excluded because of extremely high initial IOP (3 cases in the B/T group), very high pachymetry values (2 cases in T/T group and 2 in B/T group), poor control of IOP (2 cases in the T/T group), substantial discomfort reported by the patient (2 cases in the L/T group), and fear of adverse effects of timolol maleate (2 cases in the B/T group). Thus, 128 cases completed the 12 months of follow-up (44 in the T/T group, 42 in the B/T group, and 42 in the L/T group).

The mean age of the overall sample was 68 years (range, 39–88 years). The ANOVA test was 0.064. The mean ages of patients in the individual treatment groups were similar, ranging from 70.95 years in the T/T group to 65.74 years
in the B/T group. Overall, 68% were women as a result of simple random sampling (50% in the T/T group, 69% in the B/T group, and 85% in the L/T group), and there were no statistically significant differences between groups. The most frequently used prior treatment was L/T and a combination of latanoprost and dorzolamide/timolol. The most common comorbidities were cataracts (72% in the T/T group, 55% in the B/T group, and 71% in the L/T group), hypertension (54% in the T/T group, 52% in the B/T group, and 42% in the L/T group), and dyslipidemia (46% in the T/T group, 23% in the B/T group, and 31% in the L/T group). The only other underlying diseases present in more than 20% of patients in a given group were diabetes (23% in the L/T group) and myopia (21% in the L/T group).

**Intraocular pressure**

The initial IOP, after 1 month without any hypotensive drugs (washout period), was between 26 and 28 mmHg (26.4 mmHg for T/T, 27.6 mmHg for L/T, and 28.0 mmHg for B/T) and showed no significant differences between groups \((P = 0.22, \text{ANOVA})\). After 1 month of treatment, IOP decreased below 21 mmHg for all combinations (Figure 1), and remained below 21 mmHg throughout follow-up.

By month 12 significant IOP reductions were observed in all the 3 treatment groups. However, mean change from baseline was significantly greater with L/T and with B/T than with T/T; by month 12 the mean IOP reduction was 9.02 mmHg for patients treated with L/T, 8.56 mmHg for B/T-treated patients, and 6.61 mmHg for patients receiving T/T.

The mean IOP reductions throughout the period of the study are summarized in Table 1.

The relative decrease in IOP at month 12 was 26.24% for T/T, 30.19% for B/T, and 32.35% for L/T.

### Table 1 Group comparisons for absolute decrease in intraocular pressure during follow-up

|          | Baseline IOP (mmHg) | Decrease in IOP in mmHg (SD) |          |
|----------|---------------------|------------------------------|----------|
|          | T/T                 | B/T                          | L/T      |
| Baseline |                     |                              |          |
| IOP      | 26.4                | 28.0                         | 27.6     |
| Month 1  | -6.56 (3.17)        | -8.88 (3.79)**               | -7.73 (4.56) |
| Month 2  | -6.36 (2.67)        | -8.61 (4.47)**               | -7.88 (4.62) |
| Month 3  | -6.50 (3.66)        | -8.69 (4.24)*                | -8.31 (4.57)' |
| Month 4  | -6.59 (3.57)        | -8.78 (4.71)*                | -7.55 (4.70) |
| Month 5  | -6.64 (3.06)        | -8.83 (4.38)**               | -7.37 (4.72) |
| Month 6  | -6.83 (3.19)        | -8.71 (4.28)**               | -8.27 (4.56) |
| Month 12 | -6.61 (2.46)        | -8.56 (3.70)**               | -9.02 (3.63) |

**Notes:** *P < 0.05; **P < 0.01 T/T vs B/T; †P < 0.05; ‡P < 0.01 T/T vs L/T; not significant if not indicated.

**Abbreviations:** SD, standard deviation; T/T, travoprost/timolol fixed combination; B/T, bimatoprost/timolol fixed combination; L/T, latanoprost/timolol fixed combination; IOP, intraocular pressure.

**Local adverse events**

In all treatment groups, the most frequently reported adverse event at 6 months was red eye (22.7% [SD 0.4] in the T/T group, 45.2% [SD 0.5] in the B/T group, and 23.8% [SD 0.4] in the L/T group), and the differences between B/T and L/T and T/T were statistically significant \((P = 0.027 \text{ vs T/T and } P = 0.039 \text{ vs L/T})\).

Dryness was reported in 22.7% (SD 0.4) of patients in the T/T group, 14.1% (SD 0.4) in the L/T group, and 9.5% (SD 0.3) in the B/T group; itching by 13.6% (SD 0.3) in the T/T group, 16.7% (SD 0.4) in the B/T group, and 14.3% (0.4) in the L/T group; and dark eye rings by 4.5% in the T/T group, 14.3% in the B/T group, and none in the L/T group. No other local adverse reaction was reported by more than 10% in a given treatment group (Figure 2).

At 12 months, for all 3 combinations, the proportion of patients with such symptoms had decreased except for dark eye rings, which increased in the T/T group to 13.6% and in the L/T group to 15.0%. Of particular note was the decrease in red eye in the B/T group from 45.2% at 6 months to 9.5% (SD 0.3) at 1 year and the complete absence of red eye in the L/T group at 1 year. Despite this decrease, the differences between B/T and L/T remained statistically significant \((P = 0.030)\).

**Discussion**

Although there are other risk factors associated with the development and progression of glaucoma besides IOP, the most widely studied and most important risk factor is IOP.\(^1,3,6\) This is also a factor that can be readily modified by pharmacological intervention. Different studies associate high IOP with damage to the optic nerve and
suggest that the onset of glaucoma is delayed and the severity reduced when IOP is reduced.²,⁴ It has been shown that 9.5% of patients with ocular hypertension (defined as IOP between 24 mmHg and 32 mmHg in one eye and between 21 mmHg and 32 mmHg in the other eye) are at risk of developing glaucoma, but this percentage falls to 4.4% if these patients are treated.³ Although the target IOP suggested in the Advanced Glaucoma Intervention Study is 18 mmHg,² the European Glaucoma Society suggests that target IOP should be set so as not to damage the optic nerve.²⁰

IOP is determined largely by the balance between production of aqueous humor and outflow.²¹ Most of the agents currently available act by increasing uveoscleral outflow of aqueous humor, as is the case of prostaglandin analogs,²² by decreasing production of aqueous humor by the ciliary body, as is the case of β-blockers,²³ or both, as is the case of alpha2-adrenergic agonists such as brimonidine.²⁴ The clinical efficacy of such substances in lowering IOP has been shown in a number of studies. Nevertheless, the targets for IOP lowering are quite stringent and may not be reached using a single agent.²¹ In this case, the idea of combining 2 agents is an attractive one, particularly if they work by different mechanisms as is the case of combinations of prostaglandins and β-blockers. Studies that compared combinations of latanoprost and timolol suggested that there was indeed an additive effect and lower IOP could be attained by such a strategy.²⁶ With the concept of combined therapy proven, it might also be expected that fixed combinations of these drugs, which can be applied in a single application, would improve the convenience of dosing and so improve adherence to treatment.²⁷ Although fixed combination treatments have been investigated,¹³–¹⁹ studies comparing the efficacy of the 3 prostaglandins fixed combinations are not available. Studies have however been conducted comparing fixed combination timolol/dorzolamide with a combination of timolol with unoprostone.²⁸ That study reported similar efficacy for the timolol/carbonic anhydrase inhibitor combination and the timolol/prostaglandin combination.

Our study aimed to assess the reduction in IOP with 3 commercially available fixed combinations for lowering IOP, namely L/T (latanoprost 50 µg and timolol 5 mg/1 mL), T/T (travoprost 40 µg and timolol 5 mg/1 mL), and B/T (bimatoprost 300 µg and timolol 5 mg/1 mL). The absolute decreases in IOP from baseline were similar to those reported in a study with the fixed combination of T/T (7–9 mmHg).¹⁶ We also recorded local adverse reactions given that the tolerability is important for ensuring adherence to medication, particularly in the case of long-term therapy required to treat chronically elevated IOP.

The 3 combinations were good depressors of the IOP and all achieved substantial reductions in the IOP. However, at 6 months, there were differences in the symptoms reported: red eye, dark eye rings, and itching were reported more often in the B/T group whereas dryness was reported more frequently in the T/T group. After 1 year of follow-up, the overall rate of adverse reactions decreased. Thus red eye decreased in all groups, and in the L/T group, no patients reported this symptom.

These results from 1 year of follow-up support the long-term efficacy of these fixed combinations. The absolute
decrease in IOP at 12 months was significantly larger for the L/T and B/T combinations than the T/T combination. For most symptoms, tolerance improved from 6 to 12 months. In particular, the number of patients with red eye decreased substantially to such an extent that, for the L/T fixed combination, no patients reported this condition. This suggests that these fixed combinations are well tolerated with the long-term use required in these patients.

Disclosure
The authors declare no conflicts of interest.

References
1. American Academy of Ophthalmology. Glaucoma. Basic and Clinical Science Course. 2007–2008; San Francisco, CA, USA.
2. The Advanced Glaucoma Intervention Study (AGIS): The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–440.
3. Kass MA, Heuer DK, Higginbotham EI, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713.
4. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–1279.
5. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498–505.
6. Leske MC, Heijl A, Hussein M, et al. Early Manifest Glaucoma Trial Group: Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48–56.
7. Mills KB. Trabeculectomy: a retrospective long-term follow-up of 444 cases. Br J Ophthalmol. 1981;65:790–795.
8. Thomas J, Simmons RJ, Belcher CD 3rd. Argon laser trabeculoplasty in the presurgical glaucoma patient. Ophthalmology. 1982;89:187–197.
9. Heel RC, Brogden RN, Speight TM, Avery GS. Timolol: a review of its therapeutic efficacy in the topical treatment of glaucoma. Drugs. 1979;17:38–55.
10. Alexander CL, Miller SJ, Abel SR. Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann Pharmacother. 2002;36:504–511.
11. Aln A, Sjørenschutz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102:1743–1752.
12. Watson PG. Latanoprost. Two years’ experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology. 1998;105:82–87.
13. Larsson LI. Effect on intraocular pressure during 24 hours after repeated administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension. J Glaucoma. 2001;10:109–114.
14. Larsson LI. The effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension. Acta Ophthalmol Scand. 2001;79:125–128.
15. Pfeiffer N; European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002;240:893–899.
16. Schuman JS, Katz GJ, Lewis RA, et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2005;140:242–250.
17. Hommer A; Ganfort Investigators Group I. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17:53–62.
18. Martinez A, Sanchez M. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin. 2007;23:1025–1032.
19. Martinez A, Sanchez M. Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients. Eye (Lond). 2009;23:810–818.
20. Bonomi L, Marchini G, Marraffa, et al. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology. 2000;107:1287–1293.
21. Seiler T, Wollensak J. The resistance of the trabecular meshwork to aqueous humor outflow. Graefes Arch Clin Exp Ophthalmol. 1985;223:88–91.
22. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297–1304.
23. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure. In the normal eye. Arch Ophthalmol. 1978;96:2045–2048.
24. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113:1514–1517.
25. Usitalo RJ, Palkama A. Long-term evaluation of timolol. Acta Ophthalmol (Copenh). 1989;67:573–581.
26. Rulo AH, Greve EL, Hoyng PF. Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol. 1994;78:899–902.
27. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995;26:233–236.
28. Day DG, Schacknow PN, Wand M, et al. Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2003;135:138–143.